Press Releases

 
Press Releases
Date Title and Summary View
Oct 30, 2017 SALT LAKE CITY, Oct. 30, 2017 (GLOBE NEWSWIRE) -- Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that six studies on Vectra® DA will be featured at the American College of Rheumatology (ACR) meeting being held Nov. 3-8, 2017 in San Diego, Calif.  Vectra DA has been show...
Oct 26, 2017 SALT LAKE CITY, Oct. 26, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today...
Oct 24, 2017 SALT LAKE CITY, Oct. 24, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN) today announced that it will hold its fiscal first-quarter 2018 sales and earnings conference call with investors and analysts at 4:30 p.m. ET on Tuesday, November 7, 2017.  During the call, Mark C. Capone, president and CEO and Bryan Riggsbee, CFO, will p...
Oct 24, 2017 SALT LAKE CITY, Oct. 24, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that it has submitted BRACAnalysis® CDx in Japan for review by the Pharmaceutical Medical Devices Agency (PMDA) and marketing approval by Ministry...
Oct 19, 2017 SALT LAKE CITY, Oct. 19, 2017 (GLOBE NEWSWIRE) -- Assurex Health, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced new positive results for the GeneSight® test in patients with Generalized Anxiety Disorder (GAD).  The study found that GeneSight guided treatment statistically signi...
Oct 18, 2017 SALT LAKE CITY, Oct. 18, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplementary premarket approval (sPMA) application for BRACAnalysis CDx® to be ...
Oct 2, 2017 SALT LAKE CITY, Oct. 02, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, continues to demonstrate an unmatched commitment to hereditary cancer risk assessment and genetic testing during Breast Cancer Awareness Month.  As the second leading form of cancer ...
Sep 15, 2017 SALT LAKE CITY, Sept. 15, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced t...
Sep 12, 2017 SALT LAKE CITY, Sept. 12, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, to...
Sep 7, 2017
Page: FirstPrevious
4
... NextLast
= add release to Briefcase